High expression levels of XBP1 are significantly associated with poor outcomes in human tumors, including prostate cancer [40], oral squamous cell carcinoma (OSCC) [42], hepatocellular carcinoma (HCC) [43], osteosarcoma [44], myeloma [45]. Here, XBP1 is linked to plasma cell myeloma.